Pharmaceutical Industry

Octapharma AG 

Lachen Sz · Since 1999

The core activity of Octapharma is the development, production and marketing of healthcare solutions, in particular plasma-based medicines that improve patients' lives. This includes plasma collection, research and development of therapeutic proteins, production of medicines and clinical testing of products. The company operates its own plasma donation centers and invests in expanding its network to ensure the availability of plasma.

OctoSwiss GmbH 

Basel · Since 2018

The core activity of OctoSwiss GmbH is the development, manufacture and marketing of pharmaceutical products, in particular medicines for the treatment of various diseases such as parasitic infections, bacterial infections, gastrointestinal disorders, respiratory diseases, hormonal disorders and other diseases. In addition, the company also offers advisory services and pharmacovigilance services.

ODI Pharma Schweiz AG 

Zug · Since 2018

The core activity of ODI Pharma is the development, production and distribution of medical cannabis in Europe. The company focuses on the manufacture of pharmaceutical cannabis products in strict compliance with EU GMP and GDP standards and supplies them to pharmacies, clinics and hospitals in 23 European countries. In addition, ODI Pharma also offers white-label services, where the company manufactures and delivers high-quality products for other brands.

Olympic Therapeutics AG 

Zug · Since 2008

Olympic Therapeutics AG develops bacteriophages for the treatment of MRSA and other bacterial infections, focusing on research and development of therapeutic phage candidates. The company’s activities include identification and development of phage candidates, intellectual property protection, and preparation for clinical development and commercialization.

Oncoteq AG 

Cham · Since 2022

The core activity of Oncoteq AG is the development of oncological treatments using artificial intelligence (AI) in the clinical stage.

OpenVial Sàrl 

Fribourg · Since 2022

OpenVial Sàrl develops, manufactures and markets packaging systems for injectable pharmaceutical solutions. Its products include oVi, a sterile, pre‑tested, double‑packed Type 1 borosilicate vial system intended for early‑stage research and R&D in pharmaceutical and biotechnology applications, with batch documentation and testing for sterility, endotoxins and particulate control.

Opterion Health AG 

Muttenz · Since 2012

The core activity of Opterion Health AG is the development and marketing of a new, non-glucose-based osmotic agent for peritoneal dialysis (PD) in patients with end-stage renal disease. The company focuses on creating an innovative product that reduces the metabolic side effects of conventional glucose-based solutions and improves the quality of life for patients.

ORACTIVE SWISS AG 

Zug · Since 2021

The core activity of ORACTIVE Swiss AG is the development of 'Super Generics', i.e. innovative medicines based on established active pharmaceutical ingredients (APIs), specifically designed to combat modern lifestyle diseases.

Orchard Therapeutics (Switzerland) GmbH 

Zug · Since 2021

OrchestratePharma GmbH 

Baar · Since 2020

OrchestratePharma GmbH is a drug development company focused on drug repurposing (DRPx) of known molecular entities, notably fexofenadine. It is developing a topical product, FexoTopic (OP2101), for treatment of mild to moderate atopic dermatitis and pursues strategic partnerships with CROs, data-science and DRPx collaborators to accelerate development.

Organon Pensionskasse Schweiz 

Lucerne · Since 2021

Orgenesis Switzerland Sàrl 

Lausanne · Since 2020

Orgenesis Switzerland Sàrl develops and implements the POCare platform for cell and gene therapies, focusing on process development, validation and automated closed‑loop bioprocessing units (OMPUL™) for decentralized point‑of‑care production.

Orio Therapeutics SA 

Monthey · Since 2023

Orio Therapeutics' core activity is the development of protein-based therapeutics for regenerative medicine, particularly for the treatment of heart attacks. The company focuses on modifying therapeutic proteins to control their localization and delivery, thereby improving efficacy and reducing dosing.

OrPha Swiss GmbH 

Küsnacht Zh · Since 2003

The core activity of OrPha Swiss is the development, manufacture and marketing of medicines for rare diseases (Orphan Diseases) and niche areas, particularly in the fields of pulmonary hypertension, infectiology and intensive and emergency medicine.

Osmopharm SA 

Bedano · Since 1994

The core activity of Osmopharm SA is the development and production of modified oral dosage forms, particularly in pellet, tablet or resin form, using advanced galenic technologies such as coating, extrusion-spheronization and ion exchange. The company also offers services such as the manufacture of hard gelatin capsules or tablets, capsule filling and packaging of pharmaceuticals. Additionally, Osmopharm supports its customers in preparing registration applications and conducting regulatory activities.

Otsuka Pharmaceutical (Switzerland) GmbH 

Glattbrugg · Since 2013

The core activity of Otsuka Pharmaceutical Europe Ltd. is the development, manufacture and marketing of pharmaceutical products and nutritional supplements (Nutraceuticals) to improve the health and well-being of people worldwide.

Packgene Biotech AG 

Zug · Since 2024

Packgene Biotech AG provides contract research and manufacturing services for cell and gene therapies, including AAV and lentivirus packaging, mRNA/LNP and plasmid production, vector design, analytical testing and GMP manufacturing services.

Palto Therapeutics AG 

Allschwil · Since 2020

Palto Therapeutics AG develops novel formulations for biological drugs, focusing on oligonucleotide-based therapeutics such as siRNAs to enable targeted cellular uptake and cytoplasmic activation. The company designs proprietary formulation and delivery strategies to address in vivo stability and achieve tissue- or cell-type-specific distribution.

PATHELEN HEALTH CARE AG 

Rorschach · Since 2014

PATHELEN HEALTH CARE AG is a biotechnology company that develops therapies for wound care and infection management, focusing on materials that physically adsorb wound exudate and address biofilms and resistant pathogens. Its portfolio includes the product PATHELEN® HYBRID and further developments such as a gel for chronic wound aftercare and a suspension for treating cystitis caused by resistant germs.

Path Pharma GmbH 

Schindellegi · Since 2023

Path Pharma GmbH is a pharmaceutical company specializing in the development, manufacture, and marketing of medicines and health products for rare diseases and oncology/hematology. The company's core activity involves providing medical products, services, and support programs for patients, caregivers, and healthcare professionals in this field. This includes the development and marketing of medicines, provision of patient support programs, conducting medical research, and collaboration with health organizations and authorities.